Bionxt Solutions talks up sublingual thin-film product

Executive Summary

• Bionxt Solutions Inc. has secured its first patent for BNT23001, a proprietary sublingual cladribine thin-film intended for the treatment of Multiple Sclerosis (MS) and Myasthenia Gravis (MG).
• The company has completed Good Manufacturing Practice (GMP) clinical batch manufacturing for BNT23001 and is preparing for a comparative human bioequivalence study scheduled for Q1 2026.
• The release highlights the commercial potential of the drug, noting that the reference drug (cladribine tablets) achieved annual sales exceeding $1 billion, and outlines the broader market opportunity for rapid-dissolving therapies in autoimmune diseases.

Key Details

• Patent Grant: Bionxt received its first patent for BNT23001, a proprietary sublingual cladribine film.
• Patent Scope: The Eurasian patent is valid through 2043 and covers over 200 million people across eight member states.
• Pipeline Status: GMP clinical batch manufacturing for BNT23001 is complete.
• Upcoming Milestone: A comparative human bioequivalence study is scheduled for the first quarter of 2026.
• Regulatory Pathway: The company expects an accelerated, bioequivalence-driven regulatory pathway because cladribine is already an approved oral tablet, which reduces development timelines and capital requirements compared to de novo drug development.
• Market Context (MS): The global MS drugs market is forecast to reach $40–$45 billion (U.S.) by 2033.
• Market Context (MG): The global MG treatment market is projected to grow to $2.7–$4.7 billion (U.S.) by 2032.
• Reference Drug Performance: The reference drug, cladribine tablets (Mavenclad), achieved annual sales exceeding $1 billion (U.S.).
• Platform Strategy: The thin-film technology is a platform-based IP architecture supporting the reformulation of multiple approved drugs across autoimmune and chronic disease categories.
• Total Addressable Market: Combined autoimmune and chronic disease markets are projected to exceed $75–$80 billion (U.S.) annually over the next decade.
• Industry Trend: The broader oral transmucosal drug delivery market is expected to grow from ~$45.8 billion (U.S.) in 2025 to ~$96.8 billion (U.S.) by 2033.

Notable Quotes

• "When up to 40 per cent of adults report difficulty swallowing pills and dysphagia affects roughly 45 per cent of patients with multiple sclerosis, the dosage form becomes a key driver of adherence -- not a secondary consideration," said Hugh Rogers, chief executive officer of Bionxt Solutions.
• "Our rapid-dissolving thin films melt under the tongue within seconds, are taken without water and are designed to support reliable, comfortable dosing in everyday life."